Company Overview
Company Type: Public Company
Website: biovaxys.com
Number of Employees: -
Ticker: BIOV (CNSX)
Year Founded: -


Business Description
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions. It has a bioproduction agreement with WuXi Biologics Limited to produce SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; and research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320. BioVaxys Technology Corp. is based in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
3.7
Total Enterprise Value
3.7
EBIT
(2.9)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(11.9)
Total Debt
0.0
Price/Tang BV
NM
Total Assets
2.7
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Passin, James Christopher
Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director
Kovan, Kenneth E.
Co-Founder, President & COO
Berd, David 
Co-Founder & Chief Medical Officer

Key Board Members
Name
Title
Passin, James Christopher
Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director
Loverock, Craig William
Director
Barrios, Yvelise 
Scientific Adviser
Chandran, Kartik 
Member of Scientific Advisory Board
Coutts, Adam 
Member of Advisory Board
Dunton, Charles J.
Member of Advisory Board
Dutton, Anthony John Guy
Independent Director
Farhi, Shmuel 
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
146 Thirtieth Street Suite 100 | Etobicoke, ON | M8W 3C4 | Canada
Phone: 646 452 7054   

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.03
Market Cap (mm)
3.7
Open
 0.03
Shares Out. (mm)
148.0
Previous Close
 0.03
Float %
82.7%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.03/ 0.03
Diluted EPS Excl. Extra Items
(0.11)
52 wk High/Low
 0.26/ 0.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0015
Avg 3M Dly Vlm (mm)
0.20
Beta 5Y
(0.41)


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:BIOV - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Lions Bay Mining Corp.
As of September 30, 2020, Lions Bay Mining Corp. was acquired by BioVaxys LLC, in a reverse merger transaction. Lions Bay Mining Corp. operates as a mineral exploration company focused on North America. It has an option to acquire 50% interest in the Fish Lake Project located in Nevada, the United States. The company was incorporated in 2018 and is based in Vancouver, Canada.

United States and Canada
Diversified Metals and Mining
-
1.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-13-2023
Jun-13-2023
Merger/Acquisition
Seller
TAETSoftware Corp
10402588 BC Ltd
BioVaxys Technology Corp. (CNSX:BIOV)
-
Mar-16-2023
Mar-16-2023
Merger/Acquisition
Buyer
TAETSoftware Corp
BioVaxys Technology Corp. (CNSX:BIOV)

1.37
Nov-28-2022
Mar-16-2023
Private Placement
Target
BioVaxys Technology Corp. (CNSX:BIOV)


0.49
Nov-10-2022
Nov-10-2022
Private Placement
Target
BioVaxys Technology Corp. (CNSX:BIOV)


0.30
Aug-04-2022
Sep-20-2022
Private Placement
Target
BioVaxys Technology Corp. (CNSX:BIOV)


0.25
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-29-2023
Strategic Alliances
BioVaxys Technology Corp. and The Ohio State University Extend Research Collaboration
Jun-13-2023
M&A Transaction Closings
10402588 BC Ltd acquired TAETSoftware Corp.
Jun-07-2023
Executive/Board Changes - Other
Biovaxys Technology Corp. Announces Corporate Secretary Changes
Jun-07-2023
Executive Changes - CFO
Biovaxys Technology Corp. Announces Chief Financial Officer Changes
Jun-06-2023
Annual General Meeting
BioVaxys Technology Corp., Annual General Meeting, Jun 06, 2023

M&A Advisors
Irwin Lowy LLP, Morgan, Lewis & Bockius LLP


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP
M&A Advisors
Irwin Lowy LLP, Morgan, Lewis & Bockius LLP
Private Placement Advisors
Canaccord Genuity Corp.


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Jul 14, 2020 06:21 AM
BIOV
BioVaxys LLC - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Jun 10, 2020 09:11 AM
BIOV
BioVaxys LLC - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Dec 09, 2019 06:22 AM
BIOV
BioVaxys LLC - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:38 AM
BIOV
BioVaxys LLC - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 10, 2019 06:45 AM
BIOV
BioVaxys LLC - Company Report
Reports
9
Infinata, Inc.
Infinata Research
Mar 11, 2019 04:51 AM
BIOV
BioVaxys LLC - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 17, 2018 05:43 AM
BIOV
BioVaxys LLC - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 10, 2018 05:03 AM
BIOV
BioVaxys LLC - Company Report
Reports
8


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Passin, James Christopher

13,677,333

9.24

0.3

May-02-2023


Kovan, Kenneth E.

6,719,529

4.54

0.1

Jul-14-2023


Berd, David 

4,996,067

3.38

0.1

Aug-02-2022


Dutton, Anthony John Guy

250,000

0.17

0.0

May-02-2023


Wang, David 

0

0.00

0.0

Apr-06-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Kovan, Kenneth E.
6,719,529
250,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Wang, David 
0
(1,492,575)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
BVX-0320 (Future), BVX-0918 (Future), BVX-0918A (Future), BVX-0922 (Future), BVX-1021 (Future), CoviDTH (Future)


Upcoming Events
Date/Time
Type
Feb-28-2024
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-29-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
News Releases
59 KB
Jun-30-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
News Releases
56 KB
Jun-29-2023
Apr-30-2023
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
Interim Financial Statements
373 KB
Jun-14-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
News Releases
50 KB
Jun-13-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
News Releases
57 KB
Jun-07-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
News Releases
57 KB
May-16-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
Management Proxy Materials
92 KB
May-16-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
Management Proxy Materials
145 KB
May-16-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
Management Proxy Materials
166 KB
May-16-2023
-
BioVaxys Technology Corp. (CNSX:BIOV)
SEDAR
Management Proxy Materials
114 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Kovan, Kenneth E. (Co-Founder, President & COO)
Jul-14-2023
Common Shares
250,000
6,295
Open Market Acquisition
3.86
Multiple
-
Jul-14-2023
Common Shares
150,000
3,689
Open Market Acquisition
-
Exchange Announcement
-
Jul-14-2023
Common Shares
100,000
2,606
Open Market Acquisition
-
Exchange Announcement
Wang, David  (Former Director)
Feb-08-2023
Common Shares
222,804
30,669
Other Acquisition
17.55
Multiple
-
Feb-08-2023
Common Shares
63,411
10,223
Other Acquisition
-
Exchange Announcement
-
Feb-08-2023
Common Shares
70,028
10,223
Other Acquisition
-
Exchange Announcement
-
Feb-08-2023
Common Shares
89,365
10,223
Other Acquisition
-
Exchange Announcement
Wang, David  (Former Director)
Nov-08-2022
Common Shares
49,382
10,245
Other Acquisition
4.05
Multiple
Wang, David  (Former Director)
Oct-04-2022
Common Shares
94,607
10,131
Other Acquisition
8.40
Multiple
Passin, James Christopher (Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director)
Sep-20-2022
Common Shares
250,000
25,741
Private Acquisition
1.86
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Passin, James Christopher
Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director
(646) 452-7054
-
jpassin@biovaxys.com
Loverock, Craig William
Director
646 452 7054
-
craig.loverock@contagiousgaming.com
Barrios, Yvelise 
Scientific Adviser
646 452 7054
-

Chandran, Kartik 
Member of Scientific Advisory Board
646 452 7054
-

Coutts, Adam 
Member of Advisory Board
646 452 7054
-

Dunton, Charles J.
Member of Advisory Board
646 452 7054
-

Dutton, Anthony John Guy
Independent Director
(604) 649-7787
-

Farhi, Shmuel 
Member of Scientific Advisory Board
646 452 7054
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Passin, James Christopher
Co-Founder, CEO, Interim CFO, Interim Company Secretary & Director
(646) 452-7054
-
jpassin@biovaxys.com
Kovan, Kenneth E.
Co-Founder, President & COO
+1 646 452 7054
-
kkovan@biovaxys.com
Berd, David 
Co-Founder & Chief Medical Officer
646 452 7054
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
